Revised "Right to Try" Bill Narrows Scope of "Eligible Illness" In Line With FDA's Recommendation; Senate Would Need To Reconsider House Bill Due To Changes

CAR-T Reimbursement: Medicare/Medicaid Painted As Biggest Barriers At ICER Forum; Early Launch Difficulties?

Prevision Policy Clips | Sanofi/Regeneron Take Tech Style Pricing Approach With Praluent

BARDA Wants Market Differentiation For Flu Vaccines To Recognize Improvements; FDA and CDC Less Willing To Emphasize Changes v. Egg-Based

Pfizer's Xeljanz for Ulcerative Colitis Headed Toward Approval As First Oral Option for Moderate to Severe Disease

Prevision Policy Clips | 340B Senate HELP Hearing Set for March 15

Prevision Policy Clips | And Then There Were None: Cigna Buying Express Scripts

Amgen Blincyto Use In MRD-Positive Patients Gets Positive Committee Vote, But Patient Identifier Itself Is Bigger Winner

FDA Commissioner Uses Bully Pulpit To Urge Better Biosimilar Coverage; AHIP Speech Is Teaser On New Regulatory Steps – But Makes Headlines On Contracting

Prevision Policy Clips | Molecular Targets in Pediatric Cancers: FDA Meeting Set For April 20

Xeljanz for UC: FDA Briefing Documents Suggest Approval Is Likely - But Not Necessarily for All Dosing Regimens Sought By Pfizer

Prevision Policy Clips | New Role For CDER’s Mullin and New Opening For Head Of Strategic Programs

CVS/Aetna Deal Has Easy Time In House Judiciary Committee: Economists Say Merger Could Drive Down Drug Prices, Expand Drug Spend

Amgen's Blincyto sBLA Tests "Minimal Residual Disease" Concept In Leukemia Indication; FDA Remains Unconvinced

Prevision Policy Clips | Gottlieb to Testify at Influenza Preparedness House Energy & Commerce Hearing

Abbvie/Biogen Withdraw MS Drug Zinbryta: Minor Commercial Setback Carries Ominous Themes For FDA Climate

Prevision Policy Clips | Tough Talk On Punishing Drug “Pushers” – And Opioid Manufacturers

Advisory Committee Tracker: Will The Streak of "No's" End In March? Amgen, Pfizer and US WorldMeds Will Try To Get To "Yes"

E&C Health Subcommittee Considers Mandatory Prescriber Education, Technical Clarification for Injectable/Implantable MAT Distribution

Prevision Policy Clips | Botoxsimilar? Mylan enters $25 mil. deal with Revance

Prevision Policy Clips | Celgene's Multiple Sclerosis NDA Receives Refuse to File Letter from FDA February 27

Prevision Policy Clips | AHRQ Plans PRO Challenge Competition

340B Update: Providers Not Ready To Talk Legislative Deal; Shift From HRSA To CMS Could Be Next Motivator

Art of the Possible or Art of the Deal? Waxman Sees Possibilities For Both Developing In Current In Drug Policy Arena

FDA Opioid Packaging Policy Moving Forward, But Not At "Blister"-ing Pace; KemPharm Apadaz May Be One Precedent To Watch